Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.

  title={Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.},
  author={Geoffrey A. Block and David P. Rosenbaum and Maria Leonsson-Zachrisson and Bergur V. Stef{\'a}nsson and Tina Ryd{\'e}n-Bergsten and Peter J Greasley and Susanne Johansson and Mikael Knutsson and Bj{\"o}rn Carlsson},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  volume={11 9},
BACKGROUND AND OBJECTIVES Interdialytic weight gain in patients on hemodialysis is associated with adverse cardiovascular outcomes and increased mortality. The degree of interdialytic weight gain is influenced by sodium intake. We evaluated the effects of tenapanor (AZD1722 and RDX5791), a minimally systemically available inhibitor of the sodium/hydrogen exchanger isoform 3, on interdialytic weight gain in patients with CKD stage 5D treated with hemodialysis. DESIGN, SETTING, PARTICIPANTS… 

Figures and Tables from this paper

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Tenapanor treatment resulted in statistically significant, dose-dependent reductions in serum phosphate concentrations in patients with hyperphosphatemia receiving hemodialysis, and diarrhea was the most common adverse event.

Evaluation of demographic and clinical risk factors for high interdialytic weight gain

  • S. Günen YılmazF. Yılmaz
  • Medicine
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2021
Age, CRP, low POsm, and pill burden were independently associated with high IDWG, and the prevalence of xerostomia and thirst was higher in HD patients with highIDWG compared to the normal IDWWG group.

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

Following a marked increase in serum FGF23 in response to withdrawal of phosphate binders, tenapanor significantly decreased serum F GF23 in patients receiving hemodialysis with hyperphosphatemia.

The Frustrating Attempt to Limit the Interdialytic Weight Gain in Patients on Chronic Hemodialysis: New Insights Into an Old Problem.

  • M. BossolaG. PepeC. Vulpio
  • Medicine
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
  • 2018
The present narrative review aims to evaluate the efficacy of various strategies proposed to limit interdialytic weight gain such as the reduction of dietary salt intake, behavioral interventions aimed at improving the adherence to fluid restriction, the improvement of xerostomia, and the use of lower dialysate sodium concentration.

The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review

Evidence identified in this systematic review indicates a relationship between HK and LIDI with mortality in patients with renal disease receiving HD, emphasizing the need for effective monitoring and management to control potassium levels both in emergency and chronic HD settings.

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers

Tenapanor treatment reduced absorption of intestinal sodium and phosphate from the gut in Japanese adults and had minimal systemic exposure and was well tolerated.

Intradialytic hypotension

Prolonged and possibly more frequent dialysis, use of biofeedback devices, dialysate cooling and limiting sodium loading are useful measures to reduce the frequency of intradialytic hypotension (IDH).

Thirst in patients on chronic hemodialysis: What do we know so far?

The physiology of thirst in patients on chronic hemodialysis is described, as well as the prevalence, its measures, the associated variables, the consequences, and the strategies for its reduction.

Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.

Administration of combination tenapanor plus phosphate binder treatment in patients receiving dialysis with hyperphosphatemia results in more pronounced reductions in intestinal phosphate absorption than if either agent is administered alone.



Interdialytic Weight Gain and Cardiovascular Outcome in Incident Hemodialysis Patients

It could be helpful to prevent excessive IDWG for improving clinical outcomes in incident HD patients, and even when residual renal function and 24-hour urine volume were adjusted, IDwG% ≥4.0 remained as a significant predictor of primary outcome.

Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients.

  • J. InrigU. Patel L. Szczech
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2007
Day-to-day variations in weight gain have a modest role in BP increases in prevalent subjects with end-stage renal disease and in prevalent hemodialysis subjects, increasing percentage of IDWG is associated with increases in predialysis BP and BP changes with hemodIALysis.

Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study.

Prolonged exposure to higher than required dialysate sodium concentrations may drive IDWG and counteract some of the purported benefits of "go-slow" (longer session length) hemodialysis.

Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis

In he modialysis patients, greater fluid retention between 2 subsequent hemodialysis treatment sessions is associated with higher risk of all-cause and cardiovascular death.

Intradialytic hypotension and risk of cardiovascular disease.

Clinical trials to ascertain causality are needed and should consider reduction in IDWG as a potential means to reduce IDH, which was potently associated with cardiovascular morbidity and mortality.

Dialysate sodium concentration and the association with interdialytic weight gain, hospitalization, and mortality.

In the absence of randomized prospective studies, the benefit of reducing IDWG by decreasing DNa prescriptions should be carefully weighed against an increased risk for adverse outcomes.

The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis.

  • M. KayıkçıoğluM. Tumuklu E. Ok
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
It is suggested that salt restriction and reduced prescription of antihypertensive drugs may limit LV hypertrophy, better preserve LV functions and reduce intradialytic hypotension in HD patients.

Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients.

  • S. SantosA. Peixoto
  • Medicine, Biology
    Clinical journal of the American Society of Nephrology : CJASN
  • 2008
Optimization of the dialysate sodium prescription is an important step in achieving sodium balance and improving blood pressure control in hypertensive hemodialysis patients.

Improving clinical outcomes among hemodialysis patients: a proposal for a "volume first" approach from the chief medical officers of US dialysis providers.

  • D. WeinerS. Brunelli A. Nissenson
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2014
Given the high morbidity and mortality rates among dialysis patients and the absence of sufficient trial data to guide most aspects of hemodialysis therapy, participants believed that immediate attempts to improve care based on quality improvement initiatives, physiologic principles, and clinical experiences are warranted until such time as rigorous clinical trial data become available.

Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients

Sodium-MRI quantitatively detects sodium stored in skin and muscle in humans and allows studying sodium storage reduction in ESRD patients, and age and VEGF-C-related local tissue-specific clearance mechanisms may determine the efficacy of tissue sodium removal with HD.